ArticleMycopathologia2025
Epidemiology, Risk Factors and Mortality of Fungal Bloodstream Infection: 14 Years of Experience at a Teaching Hospital.
Article in Mycopathologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- A Review of the Therapeutic Challenges and Novel Treatment Options in Mitigating Invasive Mycosis Associated withJournal of fungi (Basel, Switzerland) · 2026Review
- A review of bloodstream infections-pathogens, pathogenesis, diagnostic strategies, treatment methods-challenges and future aspects.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Retrospective analysis of the epidemiological characteristics, risk factors, survival rate, and drug resistance of candidemia and construction of a logistic regression prediction model (2013-2024).BMC infectious diseases · 2026Article
- Bloodstream Infections in Solid Malignancies: Risk Factors, Resistance Patterns, and Clinical Outcomes from a Two-Center Cohort in Heraklion, Crete.Life (Basel, Switzerland) · 2026Article
- Epidemiology, risk factors, and mortality of Candida bloodstream infection in Yulin, China: a 7-year retrospective study.BMC infectious diseases · 2026Article
- Shifting Paradigms in Antifungal Prophylaxis and Their Effects on Candidemia Outcomes in Hematological Malignancies: A 14-Year Experience from a Single Tertiary Center.Journal of fungi (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal bloodstream infection is a severe condition associated with high mortality rates. Major risk factors of fungal bloodstream infection (BSI) include immunosuppression, abdominal surgery and malignancy. The epidemiology and underlying morbidities vary by geographic region and institute. We analyzed the species distribution, antifungal susceptibility, risk factors and mortality of fungal bloodstream infection at our institute over a 14-year period. Four-hundred and fourteen episodes were detected, and the average annual incidence was 0.23/1000 admissions. The most frequent species was Candida albicans (54%), followed by C. glabrata (16%). Abdominal surgery (48.3%), a solid tumor (31.4%), and immunosuppression (26.3%) were identified as major risk factors. Abdominal surgery was more prevalent in patients suffering from BSI caused by C. albicans or C. glabrata. C. tropicalis and C. albicans were associated with increased mortality in patients with neutropenia and/or immunosuppression. Azole prophylaxis in patients suffering from a hematologic malignancy or who recently had undergone organ transplantation increased the risk of C. krusei BSI. Overall 30-day mortality was 45.7% in any fungal BSI. Mortality of C. tropicalis BSI (59.4%) was the highest. Acquired antifungal resistance was not detected during the study period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.